Company

Company

Content: company-destacado-1

We improve the health and well-being of patients around the world.

Content: company-destacado-2

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Commitment

Commitment

Content: commitment-destacado-1

Patients inspire the work we do every day.

Content: commitment-destacado-2

We support the development of the scientific community and its research efforts.

Innovation

Innovation

Content: innovation-destacado-1

Take a look at the portfolio of products and therapies currently in development.

Content: innovation-destacado-2

AMBAR, an ambitious research project on Alzheimer's.

Team

Team

Content: team-destacado-1

We strive to cultivate a friendly, diverse and inclusive work environment.

Content: team-destacado-2

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Products and services

MEDIA

Latest news

08 jan, 2019 Grifols receives FDA approval of Erytra Eflexis^®, the latest advancement in scalable blood typing solutions
Read more

19 dec, 2018 Grifols partners with the Republic of Liberia to explore an innovative approach to combat Ebola virus disease
Read more

15 nov, 2018 Grifols introduces AlfaCare in Spain, the first support program for patients with Alpha-1 Antitrypsin Deficiency (AATD)
Read more

Media contacts

Journalist or media professional?

Our Media Relations team is available at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

Discover our new corporate site

Latest news

Media contacts